Core Viewpoint - A total of 14 listed companies announced share buybacks or increases in shareholdings this week, with significant involvement of loans for these activities [1][2]. Group 1: Companies Announcing Buybacks or Increases - Kailong High-Tech plans to repurchase shares worth between 25 million to 50 million yuan, with a loan of 25 million yuan [2]. - Hunan Haili intends to repurchase between 8.38 million to 16.76 million shares, supported by a loan of 200 million yuan [2]. - Guangda Special Materials aims to repurchase shares worth between 200 million to 400 million yuan, with a loan not exceeding 360 million yuan [2]. - Dahao Technology's controlling shareholder plans to increase shareholdings by 50 million to 100 million yuan [2]. - Qianhong Pharmaceutical's actual controller intends to continue increasing holdings by no less than 12.4 million shares [2]. - Bluetian Gas's controlling shareholder plans to increase holdings by 100 million to 150 million yuan, with a loan not exceeding 135 million yuan [2]. - Aikedi plans to repurchase shares worth between 100 million to 200 million yuan [2]. - Sichuan Changhong intends to repurchase shares worth between 250 million to 500 million yuan, with a loan not exceeding 450 million yuan [2]. - Qizhong Technology plans to repurchase shares worth between 75 million to 150 million yuan [2]. - Oriental Bio's chairman proposed a repurchase of shares not exceeding 50 million yuan [2]. - Yunlu Co. plans for directors and senior management to collectively increase holdings by 4 million to 12 million yuan [2]. - Hongli Zhihui's controlling shareholder plans to increase holdings by 25 million to 50 million yuan, with a loan not exceeding 45 million yuan [2]. - Dongfang Shenghong's controlling shareholder intends to increase holdings by 500 million to 1 billion yuan, with a loan not exceeding 900 million yuan [2]. - Midea Group plans to repurchase shares worth between 5 billion to 10 billion yuan, with a loan not exceeding 9 billion yuan [2].

Core Viewpoint - The company, Zhejiang Oriental Gene Biotech Co., Ltd., reported a slight increase in revenue for 2024, but a significant loss in net profit, primarily due to a decline in domestic sales and a contrasting increase in international sales [1][2]. Revenue Analysis - The company's total revenue for 2024 was 828 million yuan, a year-on-year increase of 0.95%, while the net profit attributable to shareholders was -529 million yuan, a year-on-year increase in loss of 33.06% [1]. - Domestic revenue was 207 million yuan, a decline of 35.7%, while international revenue reached 605 million yuan, an increase of 23.14% [1][2]. - The overall product sales volume decreased by 16.1% in 2024 [1]. Product Sales Breakdown - Domestic sales were primarily from the infectious disease testing series, which accounted for 39.52% of domestic revenue, but saw a volume decrease of 21.70% [1]. - The COVID-19 testing series generated 55.33% of domestic revenue but experienced a significant volume decline of 75.37% [1]. - Internationally, the drug testing series accounted for 49.67% of revenue, with a slight increase in sales volume [1][2]. Customer Analysis - The top domestic customers included new clients from trade and existing clients in infectious disease testing, with significant fluctuations in sales due to the COVID-19 product line [2]. - Internationally, major clients included large chain pharmacies in the U.S. and new clients in Mexico, contributing to the overall revenue growth [2][3]. Cost and Profit Margin - The company's operating costs for 2024 were 554 million yuan, an increase of 21.26%, with direct materials and manufacturing costs rising by 15.91% and 54.36%, respectively [5]. - The gross profit margins for domestic and international sales were 54.26% and 24.07%, respectively, both showing a decline compared to the previous year [5][6]. Market Dynamics - The decline in domestic sales was attributed to a significant drop in COVID-19 product sales, while international sales benefited from acquisitions and new product launches [3][5]. - The company expanded its market presence in Africa and introduced new online sales models, contributing to the increase in international revenue [3][4].

证券代码：688298 证券简称：东方生物 公告编号：2025-025 浙江东方基因生物制品股份有限公司 关于董事长提议回购公司部分股份的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"本公司"或"公司"）于 2025年6月17日收到公司董事长方剑秋先生（以下简称"提议人"）《关于提议 浙江东方基因生物制品股份有限公司回购公司部分股份的函》，具体内容如下： 一、提议人的基本情况及提议时间 1、提议人：公司董事长方剑秋先生 2、提议时间：2025 年 6 月 17 日 二、提议回购股份的原因和目的 本着增强投资者信心，稳定及提升公司价值，以及对公司未来发展的信心， 公司董事长方剑秋先生提议公司通过集中竞价交易方式回购部分公司股份，将用 于维护公司价值及股东权益。 上述回购股份的用途符合《上海证券交易所上市公司自律监管指引第 7 号— —回购股份》第二条第（四）项第一款所指情形：公司股票收盘价格低于最近一 期每股净资产。 三、提议内容 1、回购股份的种类：公司发行的人民币 ...

浙江东方基因生物制品股份有限公司 关于上海证券交易所对公司 2024 年年度报告 信息披露监管问询函的回复 证券代码：688298 证券简称：东方生物 公告编号：2025-024 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"、"公司"、 "本公司"）于近日收到上海证券交易所《关于浙江东方基因生物制品股份有限 公司 2024 年年度报告的信息披露监管问询函》（上证科创公函【2025】0152 号）， 现将问询函的相关问题做如下补充说明： 一、关于营业收入。公司主营业务为体外诊断试剂。2024 年，公司营业收 入为 8.28 亿元，同比增长 0.95%，归母净利润为-5.29 亿元，同比增亏 33.06%。 其中，境外收入 6.05 亿元，同比增长 23.14%；境内收入 2.07 亿元，同比下 滑 35.7%。公司 2024 年产品销量同比减少 16.1%。公司综合毛利率同比减少 12 个百分点。 请公司：（1）列示 2024 年境内主要销售产品类型、用途、收入金额、 ...

立信会计师事务所(特殊普通合伙) 关于浙江东方基因生物制品股份有限公司 2024年年度报告信息披露监管问询函的回复 信会师函字[2025]第 ZF171 号 上海证券交易所: 根据贵所《关于对浙江东方基因生物制品股份有限公司 2024 年年度报告的 信息披露监管问询函》(以下简称"问询函")(上证科创公函【2025】第 0152 号)的要求,立信会计师事务所(特殊普通合伙)(以下简称"会计师"或"我们") 作为浙江东方基因生物制品股份有限公司(以下简称"公司"或"东方生物")2024 年度财务报表审计机构,对问询函中与会计师相关的内容作了认真核查,现回复 如下: 问题 1、关于营业收入。公司主营业务为体外诊断试剂。2024年,公司营 业收入为 8.28 亿元,同比增长 0.95%,归母净利润为-5.29 亿元,同比增亏 33.06%。其中,境外收入 6.05 亿元,同比增长 23.14%;境内收入 2.07 亿元, 同比下滑 35.7%。公司 2024 年产品销量同比减少 16.1%。公司综合毛利率同 比减少 12 个百分点。 请公司:(1)列示 2024 年境内主要销售产品类型、用途、收入金额、收 入占比及 ...

上述证书的取得，进一步完善了公司在国内传染病检测领域的产品系列，丰 富了流式荧光（液态生物芯片）用于消化道等恶性肿瘤的疗效观察、预后判断及 复发检测、治疗监测等领域的配套检测试剂，扩展了流式荧光发光法的应用领域， 有利于国内市场的整体拓展。 三、风险提示 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 浙江东方基因生物制品股份有限公司（以下简称"东方生物"或"公司"） 及子公司上海万子健生物科技有限公司近日取得以下中国医疗器械注册证（体外 诊断试剂），相关证书内容公告如下： | 产品名称 | 证书编号 | 预期用途 | 有效期 | 持证主体 | | --- | --- | --- | --- | --- | | 乙型肝炎病毒表面抗原 | 国械注准 | 本产品用于体外定性检测人全 | 2025/5/29 | | | （HBsAg）检测试剂(胶体金 | | 血/血清/血浆样本中的乙型肝 | -2030/5/2 | 东方生物 | | 法) | 20253401025 | 炎病毒表面抗原（HBsAg） | 8 | | | | | ...

Core Insights - The company has successfully developed a liquid chip platform that addresses a critical technology bottleneck in the in vitro diagnostic (IVD) field, previously dominated by foreign giants [1][2][3] - The liquid chip technology is recognized as a key area for innovation in China's "13th Five-Year" national science and technology plan, highlighting its importance for future diagnostic advancements [2] - The platform has been implemented in several renowned hospitals in Shanghai and the Southwest region, providing reliable diagnostic support for tumor markers and autoimmune diseases [1][7] Technology and Innovation - The liquid chip technology utilizes special fluorescent polymer microspheres and signal analysis, overcoming high technical barriers that have historically limited domestic capabilities [2][3] - The core breakthrough involves the use of quantum dot materials for microsphere encoding, allowing for the analysis of over 100 coding signals and enhancing the capacity to thousands with 3D encoding technology [2][4] - The company has established a comprehensive intellectual property system covering the entire supply chain from raw materials to end instruments and reagents, eliminating reliance on foreign technologies [3][4] Product Development and Market Expansion - The company has launched the Mplex-MA1600, the first dual-function immunoassay analyzer in the industry, integrating flow fluorescence and chemiluminescence technologies for efficient multi-item and rapid single-item testing [4][5] - Since July 2023, the company has received 13 NMPA registration certificates for reagents in various fields, including tumor markers and autoimmune diseases, with plans to expand the range of detectable markers [5][6] - The liquid chip technology is also being applied in animal testing and food safety, with collaborations with several research institutes to develop diagnostic kits for various pathogens in livestock [6][7] Competitive Advantage - The company has achieved a breakthrough in "higher performance and lower cost" compared to international leader Luminex, thanks to its fully controllable domestic platform [1][7] - The new detection system combines quantum dot encoding microspheres with single-laser detection technology, achieving high throughput (120 samples/hour), high sensitivity (pg/mL level), and high accuracy (CV < 5%) [7] - The compact design of the fully automated detection equipment reduces the footprint by approximately 40% and lowers overall detection costs by about 50%, facilitating widespread adoption [7]

Group 1 - The animal vaccine sector increased by 1.35%, ranking fourth among concept sectors, with 13 stocks rising, including Kexing Pharmaceutical, Kanghua Biological, and Dongfang Biological, which rose by 7.40%, 6.06%, and 5.85% respectively [1][2] - The leading stocks in terms of net inflow of main funds include Tiankang Biological with a net inflow of 17.69 million, followed by Dongfang Biological, Dabeinong, and Haizheng Pharmaceutical with net inflows of 17.19 million, 7.87 million, and 5.25 million respectively [2][3] - The main fund inflow rates for Dongfang Biological, Haili Biological, and *ST Xianfeng are 9.15%, 6.15%, and 5.51% respectively [3] Group 2 - The top gainers in the animal vaccine sector include Kexing Pharmaceutical with a rise of 7.40% and Kanghua Biological with a rise of 6.06%, while the biggest losers include Weilan Biological, Jinhai Biological, and Plai Ke, which fell by 1.82%, 1.26%, and 1.08% respectively [1][4] - The overall net outflow of main funds from the animal vaccine sector was 4.75 million, indicating a mixed sentiment among investors [2]

Group 1 - The annual general meeting of Zhejiang Oriental Gene Biological Products Co., Ltd. was held on May 28, 2025, at the company's conference room in Anji County, Huzhou City, Zhejiang Province [2] - All resolutions presented at the meeting were approved without any objections [2] - The meeting was conducted in accordance with the Company Law, Securities Law, and the company's articles of association, with a combination of on-site and online voting [2][3] Group 2 - All current directors (7) and supervisors (3) attended the meeting, along with the company secretary and senior management [3] - The following non-cumulative voting proposals were approved: 2024 Board Work Report, 2024 Supervisory Board Work Report, 2024 Financial Settlement Report, 2024 Annual Profit Distribution Plan, 2024 Annual Report and Summary, 2025 Financial Budget Report, 2025 Director Remuneration Plan, 2025 Supervisor Remuneration Plan, and the proposal to reappoint the auditing firm for 2025 [4][5] - The meeting did not involve any special resolutions, and certain proposals required abstention from related shareholders [6] Group 3 - The meeting was witnessed by lawyers from Guohao Law Firm (Hangzhou), confirming that the meeting's procedures and results were legal and valid [7] - The company will file the meeting resolutions and legal opinions as required [9]

一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 5 月 28 日 （二） 股东大会召开的地点：浙江省湖州市安吉县递铺街道阳光大道东段东方 基因会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： 证券代码：688298 证券简称：东方生物 公告编号：2025-023 浙江东方基因生物制品股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 | 1、出席会议的股东和代理人人数 | 85 | | --- | --- | | 普通股股东人数 | 85 | | 2、出席会议的股东所持有的表决权数量 | 99,235,127 | | 普通股股东所持有表决权数量 | 99,235,127 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 51.3649% | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 51.3649% | ...